id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cajgh-154	Bektur, Carina; Nurgozhin, Talgat	Cost-effectiveness Analysis of Denosumab in the Prevention of Skeletal-related Events in Patients with Prostate Cancer in Kazakhstan	2014	2	.pdf	application/pdf	553	30	47	Direct costs (in Kazakhstani monetary units “tenge” in 2014) included costs of drug, SRE (pathologic fracture, surgery to bone, radiation to bone, spinal cord compression), and adverse events treatment. Over the 10-year period, denosumab incurred 103,091 tenge higher costs than brand ZA, 677,133 tenge higher costs than generic ZA, and 0.58 fewer SREs per patient with PC.	cache/cajgh-154.pdf	txt/cajgh-154.txt